Medindia LOGIN REGISTER
Medindia
Advertisement

Tumor Cells in Blood Calls for Poor Prognosis in Early Breast Cancer

by Dr. Enozia Vakil on May 17, 2014 at 3:22 PM
 Tumor Cells in Blood Calls for Poor Prognosis in Early Breast Cancer

Presence of tumor cells in the bone marrow of early breast cancer patients may predict a higher risk of relapse and poorer survival, but bone marrow biopsy is a painful and invasive procedure. Now, it may be possible to identify tumor cells in a routine blood sample and use them as prognostic markers, according to a study published May 15 in the Journal of the National Cancer Institute.

To assess the prognostic value of circulating tumor cells (CTCs) in patients with early breast cancer, Brigitte Rack, M.D., of the Department of Gynecology and Obstetrics, Klinikum Innenstadt, Ludwig-Maximilians-Universitaet Muenchen, in Munich, Germany, and colleagues analyzed CTCs in peripheral blood from patients from the SUCCESS trial. Samples were taken from 2026 patients after primary surgery and before systemic treatment and in 1492 patients after chemotherapy.

Advertisement

The patients were classified into four groups: positive for CTCs both before and after treatment, negative for CTCs both before and after, positive for CTCs before but negative after, and negative CTCs before but positive after treatment. Those with positive CTCs both before and after treatment had the worst disease-free survival compared to the other three groups. Overall, the probability of being disease-free at 36 months after surgery was lower for patients with CTCs than for patients without, and of those patients who died during follow-up, 40.9% had CTCs in their blood compared to 20.8% of patients who survived. In addition, the greater the CTC count, the worse the prognosis. Patients with 5 or more CTCs in 30ml of blood were at higher risk of recurrent disease.

The authors conclude that "Our data offer support for the clinical potential of CTCs to assess the individual risk of patients at the time of primary diagnosis and may be used for treatment tailoring in the absence of other strong quantitative markers." However, they note that although they used only two markers to detect CTCs, the identification of other markers could make CTCs even more useful in predicting metastases and guiding therapeutic choices.
Advertisement

In an accompanying editorial, Arnold M. Schwartz, M.D., Ph.D., of the Department of Pathology and Surgery and Norris Nolan, M.D., of the Department of Pathology at The George Washington University, Washington, DC, write that the work of Rack et al. is notable because of the large cohort, the focus on early breast cancer, and sampling both before and after treatment and that "The identification of CTCs represents an additional biomarker that provides insight into clinical behavior."
Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

Does Twice Daily Stimulation Enhance Alzheimer's Mental Functions?
Electrical stimulation improves Alzheimer's patients' cognitive function and correlates with restored cortical plasticity.
South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Tumor Cells in Blood Calls for Poor Prognosis in Early Breast Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests